Navigation Links
After a Stroke, When Seconds Count, Innovative Device from NeuroInterventions Speedily Restores Brain's Blood Flow
Date:10/11/2009

WASHINGTON, Oct. 11 /PRNewswire/ -- A new device from NeuroInterventions, Inc., is designed to minimize brain damage by dramatically speeding the delivery of post-stroke countermeasures.

"Stroke is the third most frequent cause of death, and the number-one cause of permanent disability," says NeuroInterventions President and COO Michele Migliuolo [mil-u-OLO]. "When a clot blocks the flow of oxygen-rich blood in the brain, the 'window' for surgical help is only a few hours wide. Every second can mean a drop in brain function."

So, driven by the emergency-room maxim, "Time is brain," NeuroInterventions has developed groundbreaking technology that enables surgeons to reach and remove clots in much less time than conventional approaches. Dr. Migliuolo will describe the development in a presentation today at AdvaMed 2009, at the Walter E. Washington Convention Center, Room 304, at 10:20 a.m.

"Even after a patient reaches a hospital, it can take up to 60 minutes just to introduce a conventional catheter through the femoral artery and steer it to the site, before you can deal with the clot," he says.

Capable of dissolving or extracting clots and delivering medication, the NeuroInterventions system takes a shorter, faster path to the brain. With exceptional maneuverability for negotiating the circulatory system, "Our devices will benefit patients, physicians, hospitals and insurance companies by improving outcomes through shorter, more effective treatment; by permitting more complex procedures; and by reducing recovery times."

Based in Pittsburgh, NeuroInterventions is prototyping a family of patent-pending catheters for addressing deep vein thrombosis, carotid stenting, and traumatic brain injury, in addition to stroke. The technology also facilitates localized drug and stem cell delivery.

On the management team are world leaders in interventional radiology, neurology and neurosurgery, as well as successful entrepreneurs, among them: Lawrence Wechsler, M.D., chair of the Department of Neurology and director of the Stroke Institute at the University of Pittsburgh Medical Center; Mark H. Wholey, M.D., founder and director of the Pittsburgh Vascular Institute; Tudor Jovin, M.D., co-director of the Center for Neuroendovascular Therapy at the University of Pittsburgh Medical Center; Ender Finol, Ph.D., associate research professor for the Institute for Complex Engineered Systems and Biomedical Engineering Department at Carnegie Mellon University; and Dr. Migliuolo, a high-tech entrepreneur and former executive in residence at the Pittsburgh Life Sciences Greenhouse.

    Media contact: Michele Migliuolo, Ph.D.
    info@neurointerventions.com
    412-663-0109

SOURCE NeuroInterventions, Inc.


'/>"/>
SOURCE NeuroInterventions, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Ekkyo Presents a Positive Assessment one Year After the Launch of EkkyLite(TM), its New Scar Healing System
2. New Reconstruction Method Makes Speaking, Eating Possible After Tonsil Cancer Surgery, U-M Study Shows
3. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
4. Study Shows Cancer Vaccines Led to Long-Term Survival for Patients with Metastatic Melanoma and to Long Periods of Disease Control After Completion of Therapy
5. UNT Health Science Centers Groundbreaking Research Applied to Protecting Brain After Traumatic Injury
6. Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
7. Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery
8. Heaviest Smokers Face Greatest Risk of Death After Lung Cancer Diagnosis
9. Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery
10. Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib
11. Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 2017 Eyevensys, a private biotechnology ... gene expression technology that enables the safe, local, sustained ... a wide range of ophthalmic diseases, announces it has ... Regulatory Agency (MHRA) to advance its technology into clinical ... The ...
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment ... projected period The Cardiology Devices segment is likely ... US$ 15 Mn in 2018 over 2017. By the end ... market valuation close to US$ 700 Mn, expanding at a ... segment dominated the Asia Pacific reprocessed ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
Breaking Medicine Technology:
(Date:4/25/2017)... Richmond, BC (PRWEB) , ... April 25, 2017 , ... ... patients from Richmond, BC, who live with dental fear and require sedation to receive ... anxiety at ease during various procedures, from hygienic cleanings to oral surgery, at ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... they rely on contracted partners to help with process innovation in drug formulation ... drug formulation experience along with state-of-the-art analytical equipment in support of their development ...
(Date:4/25/2017)... MN (PRWEB) , ... April 25, 2017 , ... Buyers ... and recreational users to dispensaries and head shops –can’t help but be heartened by ... for the tell-tale cannabis odor aptly described as “skunk smell.” At last they ...
(Date:4/25/2017)... ... 25, 2017 , ... Emergency Physician and Distinguished Professor of Emergency Medicine Bentley ... in Writing, set to publish in summer 2017. , Dr. Bobrow, MD, FACEP, ... Arizona College of Medicine. He also serves as Medical Director for the Bureau of ...
(Date:4/25/2017)... ... April 25, 2017 , ... Amendia, Inc., designer, developer, and ... partnership with and platinum sponsorship of Global Spine Outreach (“GSO”), a charitable organization ... of complex spine deformity cases, particularly in children. , GSO’s focus is to ...
Breaking Medicine News(10 mins):